| Autor: |
Martínez-Reyes CP; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Gómez-Arauz AY; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Torres-Castro I; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Manjarrez-Reyna AN; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Palomera LF; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Olivos-García A; Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico., Mendoza-Tenorio E; Departamento de Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico., Sánchez-Medina GA; Research Division, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Islas-Andrade S; Research Division, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Melendez-Mier G; Research Division, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico., Escobedo G; Unit of Experimental Medicine, School of Medicine, National University of Mexico, General Hospital of Mexico 'Dr. Eduardo Liceaga', 06726 Mexico City, Mexico. |
| Abstrakt: |
Experimental evidence in mice suggests a role for interleukin- (IL-) 13 in insulin resistance and low-grade systemic inflammation. However, IL-13 serum levels have not been assessed in subjects with insulin resistance, and associations of IL-13 with parameters of low-grade systemic inflammation are still unknown. Our main goal was to examine the systemic levels of IL-13 in patients with insulin resistance, while also studying the relationship of IL-13 with anthropometric, metabolic, and low-grade systemic inflammatory markers. Ninety-two participants were included in the study and divided into insulin-resistant patients and noninsulin-resistant controls. Blood levels of IL-13, glucose, insulin, triglycerides, cholesterol, tumor necrosis factor-alpha (TNF- α ), IL-10, proinflammatory (Mon-CD11c + CD206 - ), and anti-inflammatory (Mon-CD11c - CD206 + ) monocytes, as well as anthropometric parameters, were measured in all volunteers. Insulin-resistant patients showed 2.5-fold higher serum levels of IL-13 than controls ( P < 0.0001) and significantly increased values of TNF- α and Mon-CD11c + CD206 - , with concomitant reductions in IL-10 and Mon-CD11c - CD206 + . Increased IL-13 was extraordinarily well associated with hyperglycemia ( r = 0.7362) and hypertriglyceridemia ( r = 0.7632) but unexpectedly exhibited no significant correlations with TNF- α ( r = 0.2907), IL-10 ( r = -0.3882), Mon-CD11c + CD206 - ( r = 0.2745) or Mon-CD11c - CD206 + ( r = -0.3237). This study demonstrates that IL-13 serum levels are elevated in patients with insulin resistance without showing correlation with parameters of low-grade systemic inflammation. |
